Bryn Pharma

No Needle GLP-1 Delivery System

About this Event

Bryn Pharma is developing an inhaled drug delivery platform that offers significant benefits over injectables in several cases.

The company has made significant progress in the development of an inhaled GLP-1.

Designed for flexible mealtime dosing, Bryn may help patients avoid GI side effects that contribute to discontinuation rates of 30-50% for long-acting injectable GLP-1s. This will help more people lower their blood sugar levels, lose weight, and reduce their risk of heart disease.

They are also developing a nasal alternative to the EpiPen which has a clear pathway to NDA submission in 2026. In clinical trials, it has been proven as effective as injected epinephrine, in a package that’s more convenient and easier to administer.

Register now to watch our fireside chat with Bryn Pharma Founder, Michelle Lobel, and CEO, Joshua Ziel, PhD, to hear how their device platform is poised to disrupt two multi-billion dollar markets.

Video On Demand

– Recorded

June 4

SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.